← Leaderboards
Eduardo Vilar Sanchez
University Of Tx Md Anderson Can Ctr
$16,310,319
Attributed
$24,840,107
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,840,107 · 10
By mechanism
UG1$9,807,930 · 1
R01$9,421,174 · 4
U01$3,761,146 · 1
N01$1,246,808 · 1
R21$395,139 · 1
R03$160,000 · 1
Top collaborators
- Steven Monroe Lipkin10 shared
- Powel H Brown4 shared
- Stanton Bradley Gray4 shared
- Roderick H Dashwood3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Susan K Peterson$7,271,594
- Ronald Anthony Depinho$97,148,322
- Richard Eric Davis$942,457
- Stanton Bradley Gray$1,360,793
- Sattva S Neelapu$3,334,171
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsColorectal CancerColorectalHereditary Nonpolyposis Colorectal NeoplasmsInnovationNon-Steroidal Anti-Inflammatory AgentsImmuneClinical TrialsPremalignantGenesBasePeptidesIncidenceLesionBiological MarkersTumorMucous MembraneNaproxenPublic HealthNeoantigensAdenomaAffectMismatch RepairGene Repair
Grant awards (38)
iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium$1,627,502
UG1 · FY2025 · CA · contact PI
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome$831,115
R01 · FY2025 · CA · contact PI
Project Title: Low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC)$691,578
N01 · FY2025 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$672,260
R01 · FY2025 · CA · contact PI
Immunoepigenetic targeting of MHC regulators in FAP$586,553
R01 · FY2025 · CA
28 Cancer Prevention$24,690
P30 · FY2025 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$1,321,621
UG1 · FY2024 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$639,370
R01 · FY2024 · CA · contact PI
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome$606,579
R01 · FY2024 · CA · contact PI
Immunoepigenetic targeting of MHC regulators in FAP$563,269
R01 · FY2024 · CA
TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION$551,730
N01 · FY2024 · CA · contact PI
28 Cancer Prevention$23,220
P30 · FY2024 · CA · contact PI
TO Title: Contract Orientation & Kickoff Meeting for Preclinical Services for PREVENTBase IDIQ Title: PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate End$3,500
N01 · FY2024 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$1,363,358
UG1 · FY2023 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$660,089
R01 · FY2023 · CA · contact PI
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome$637,581
R01 · FY2023 · CA · contact PI
Immunoepigenetic targeting of MHC regulators in FAP$605,411
R01 · FY2023 · CA
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$911,328
UG1 · FY2022 · CA
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$780,309
U01 · FY2022 · CA
Cancer Immune-Interception for Lynch Syndrome$661,865
R01 · FY2022 · CA · contact PI
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome$646,311
R01 · FY2022 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$1,822,363
UG1 · FY2021 · CA
Cancer Immune-Interception for Lynch Syndrome$692,579
R01 · FY2021 · CA · contact PI
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$638,061
U01 · FY2021 · CA
Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome$320,000
R01 · FY2021 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$1,814,563
UG1 · FY2020 · CA
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$771,608
U01 · FY2020 · CA
Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome$324,218
R01 · FY2020 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$947,195
UG1 · FY2019 · CA
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$717,507
U01 · FY2019 · CA
Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome$317,580
R01 · FY2019 · CA · contact PI
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$853,661
U01 · FY2018 · CA
Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome$325,719
R01 · FY2018 · CA · contact PI
Uncovering Gene Expression Differences between Benign and Premalignant Colorectal Polyps$175,237
R21 · FY2018 · CA · contact PI
Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome$330,675
R01 · FY2017 · CA · contact PI
Uncovering Gene Expression Differences between Benign and Premalignant Colorectal Polyps$219,902
R21 · FY2017 · CA · contact PI
Discovering New Targets for Chemoprevention in Familial Adenomatous Polyposis$80,000
R03 · FY2015 · CA · contact PI
Discovering New Targets for Chemoprevention in Familial Adenomatous Polyposis$80,000
R03 · FY2014 · CA · contact PI